{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:18:53Z","timestamp":1791875933164,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejmech.2025.117634","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:58:55Z","timestamp":1744973935000},"page":"117634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Challenging triple negative breast cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies"],"prefix":"10.1016","volume":"292","author":[{"given":"Simona","family":"Barone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guadagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cerchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica","family":"Filocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Ilenia","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro Javier","family":"Feliz Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-3773","authenticated-orcid":false,"given":"Margherita","family":"Brindisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117634_bib3","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1039\/C6CS00599C","article-title":"Epigenetic modification of nucleic acids: from basic studies to medical applications","volume":"46","author":"Chen","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117634_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2025.117634_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116884","article-title":"Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform","volume":"279","author":"Guadagni","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117634_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117634_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060667","article-title":"HDAC inhibitors for the therapy of triple negative breast cancer","volume":"15","author":"Maccallini","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"42","key":"10.1016\/j.ejmech.2025.117634_bib8","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117634_bib9","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1021\/acs.jmedchem.1c02067","article-title":"Chasing a breath of fresh air in cystic fibrosis (CF): therapeutic potential of selective HDAC6 inhibitors to tackle multiple pathways in CF pathophysiology","volume":"65","author":"Barone","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117634_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117634_bib11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: a unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117634_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"31","key":"10.1016\/j.ejmech.2025.117634_bib13","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117634_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.drudis.2015.01.007","article-title":"Histone deacetylases: structural determinants of inhibitor selectivity","volume":"20","author":"Micelli","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117634_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nchembio.2158","article-title":"Structural biology: HDAC6 finally crystal clear","volume":"12","author":"Liu","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117634_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117634_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2018.07.069","article-title":"Novel spiroindoline HDAC inhibitors: synthesis, molecular modelling and biological studies","volume":"157","author":"Brindisi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117634_bib18","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1021\/acsmedchemlett.0c00395","article-title":"Spiroindoline-capped selective HDAC6 inhibitors: design, synthesis, structural analysis, and biological evaluation","volume":"11","author":"Saraswati","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117634_bib19","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117634_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of triple negative breast cancer","volume":"72","author":"Borri","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117634_bib21","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117634_bib22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117634_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117634_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer","volume":"54","author":"Kumar","year":"2023","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117634_bib26","first-page":"1622","article-title":"Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer","volume":"5","author":"Lu","year":"2024","journal-title":"Nat. Can. (Ott.)"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc4897","article-title":"Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer","volume":"7","author":"Dowling","year":"2021","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117634_bib28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117634_bib29","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-15-2478","article-title":"EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90527-6","article-title":"HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation","volume":"11","author":"Alothaim","year":"2021","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117634_bib31","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1021\/acs.jmedchem.0c00688","article-title":"Novel autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis: a clinical candidate discovered using DNA-encoded chemistry","volume":"63","author":"Cuozzo","year":"2020","journal-title":"J. Med. Chem."},{"issue":"37","key":"10.1016\/j.ejmech.2025.117634_bib32","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.2174\/0929867324666170209105315","article-title":"Progress in the discovery of macrocyclic histone deacetylase inhibitors for the treatment of cancer","volume":"24","author":"Cheng","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117634_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/1568026615666150813145218","article-title":"Metalloprotein inhibitors for the treatment of human diseases","volume":"16","author":"Yang","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117634_bib34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117634_bib35","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1039\/c1cs15119c","article-title":"New and unusual scaffolds in medicinal chemistry","volume":"40","author":"Marson","year":"2011","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117634_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17460441.2016.1195367","article-title":"The utilization of spirocyclic scaffolds in novel drug discovery","volume":"11","author":"Zheng","year":"2016","journal-title":"Expet Opin. Drug Discov."},{"issue":"31","key":"10.1016\/j.ejmech.2025.117634_bib37","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.2174\/0929867325666180309124821","article-title":"Advances in spirocyclic hybrids: chemistry and medicinal actions","volume":"25","author":"Benabdallah","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/chem.201604714","article-title":"Charting biologically relevant spirocyclic compound space","volume":"23","author":"Muller","year":"2017","journal-title":"Chemistry"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117634_bib39","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117634_bib40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/cbdd.12260","article-title":"Two- and three-dimensional rings in drugs","volume":"83","author":"Aldeghi","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"issue":"21\u201322","key":"10.1016\/j.ejmech.2025.117634_bib41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","article-title":"The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?","volume":"14","author":"Ritchie","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"21","key":"10.1016\/j.ejmech.2025.117634_bib42","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1039\/c2md20347b","article-title":"Escape from flatland 2: complexity and promiscuity","volume":"4","author":"Lovering","year":"2013","journal-title":"Medchemcomm"},{"issue":"16","key":"10.1016\/j.ejmech.2025.117634_bib44","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1016\/j.bmcl.2014.06.081","article-title":"The use of spirocyclic scaffolds in drug discovery","volume":"24","author":"Zheng","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/acs.jmedchem.0c01473","article-title":"Spirocyclic scaffolds in medicinal chemistry","volume":"64","author":"Hiesinger","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17460441.2024.2305735","article-title":"Have spirocyclic scaffolds been properly utilized in recent drug discovery efforts?","volume":"19","author":"Benedetti","year":"2024","journal-title":"Expet Opin. Drug Discov."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117634_bib47","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone deacetylase 6-Selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejmech.2025.117634_bib48","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/acs.biochem.8b00367","article-title":"Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6","volume":"57","author":"Porter","year":"2018","journal-title":"Biochemistry"},{"issue":"51","key":"10.1016\/j.ejmech.2025.117634_bib49","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117634_bib50","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/acs.orglett.8b01118","article-title":"Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors","volume":"20","author":"Mackwitz","year":"2018","journal-title":"Org. Lett."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117634_bib51","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/acsmedchemlett.1c00425","article-title":"Role of fluorination in the histone deacetylase 6 (HDAC6) selectivity of Benzohydroxamate-Based inhibitors","volume":"12","author":"Sandrone","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117634_bib52","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117634_bib53","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117634_bib54","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","article-title":"Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors","volume":"62","author":"Vogerl","year":"2019","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117634_bib55","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.1c00184","article-title":"Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors","volume":"64","author":"Campiani","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117634_bib56","first-page":"971","article-title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B","volume":"2","author":"Fuino","year":"2003","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1535-7163.MCT-06-0125","article-title":"Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma","volume":"6","author":"Kato","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117634_bib58","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1021\/acs.biochem.2c00332","article-title":"Aromatic ring fluorination patterns modulate inhibitory potency of fluorophenylhydroxamates complexed with histone deacetylase 6","volume":"61","author":"Watson","year":"2022","journal-title":"Biochemistry"},{"issue":"18","key":"10.1016\/j.ejmech.2025.117634_bib59","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1021\/jm400385r","article-title":"Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform","volume":"56","author":"Blackburn","year":"2013","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117634_bib60","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1021\/jm301098e","article-title":"Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth","volume":"55","author":"Bergman","year":"2012","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117634_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127023","article-title":"Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6","volume":"30","author":"Osko","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117634_bib62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","article-title":"HDAC8: a multifaceted target for therapeutic interventions","volume":"36","author":"Chakrabarti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117634_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","article-title":"Class I HDACs share a common mechanism of regulation by inositol phosphates","volume":"51","author":"Millard","year":"2013","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117634_bib64","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500399X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500399X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:08:40Z","timestamp":1762265320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500399X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"alternative-id":["S022352342500399X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117634","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging triple negative breast cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117634"}}